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Aims The aim of the study was to examine whether differences in average diameter of low-density lipoprotein (LDL) particles
were associated with total and cardiovascular mortality.
Methods and
results
We studied 1643 subjects referred to coronary angiography, who did not receive lipid-lowering drugs. During a median
follow-up of 9.9 years, 398 patients died, of these 246 from cardiovascular causes. We calculated average particle dia-
meters of LDL from the composition of LDL obtained by b-quantification. When LDL with intermediate average dia-
meters (16.5–16.8 nm) were used as reference category, the hazard ratios (HRs) adjusted for cardiovascular risk
factors for death from any cause were 1.71 (95% CI: 1.31–2.25) and 1.24 (95% CI: 0.95–1.63) in patients with large
(.16.8 nm) or small LDL (,16.5 nm), respectively. Adjusted HRs for death from cardiovascular causes were 1.89
(95% CI: 1.32–2.70) and 1.54 (95% CI: 1.06–2.12) in patients with large or small LDL, respectively. Patients with large
LDL had higher concentrations of the inflammatory markers interleukin (IL)-6 and C-reactive protein than patients
with small or intermediate LDL. Equilibrium density gradient ultracentrifugation revealed characteristic and distinct pro-
files of LDL particles in persons with large (approximately even distribution of intermediate-density lipoproteins and
LDL-1 through LDL-6) intermediate (peak concentration at LDL-4) or small (peak concentration at LDL-6) average
LDL particle diameters.
Conclusions Calculated LDL particle diameters identify patients with different profiles of LDL subfractions. Both large and small LDL
diameters are independently associated with increased risk mortality of all causes and, more so, due to cardiovascular
causes compared with LDL of intermediate size.
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Introduction
Low-density lipoproteins (LDL) include a heterogeneous mixture of
particles which can be separated by ultracentrifugation,1– 3 chroma-
tography,4 nuclear magnetic resonance spectroscopy,5 or gradient
gel electrophoresis.6 Experimental and turnover studies have
raised the possibility that dense LDL may be more atherogenic
than buoyant LDL. Potential mechanisms include easier transfer of
dense LDL from the vessel lumen into the subintimal space,7
decreased binding to LDL receptors and increased plasma residence
time,8 –11 and higher affinity to proteoglycans compared with
buoyant LDL.12,13
Dense LDL have been linked to surrogate vascular endpoints
including endothelial dysfunction14 or carotid intima media
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thickness.15,16 Prospective epidemiological studies have mostly used
gradient gel electrophoresis to investigate the relationship between
LDL subfractions and coronary artery disease (CAD). However,
results have not been consistent. Predominance of small dense
LDL was indeed found associated with CAD, but overall the link
wasnot independent from lowhigh-density lipoproteins (HDL)choles-
terol (HDL-C) and/or high triglyerides (TG).17–21 Further studies have,
in contrast, claimed that small dense LDL are associated with CAD in-
dependent of low-density lipoprotein cholesterol (LDL-C) and
HDL-C, TG or lipoprotein(a).22,23 Finally, others claim that buoyant
LDL may be more atherogenic than dense ones.24,25 In studies using
nuclear magnetic resonance spectroscopy, small and large LDL were
associated with atherosclerosis and CAD, but the LDL size was no
longer predictive after adjustment for lipid parameters.26–28 These
controversial findings prompted us to examine whether mean LDL
particle diameters are related to total and cardiovascular mortality
and, if such a relationship would exist, whether it is independent from
the major lipid parameters and established risk factors for CAD.
Methods
Ludwigshafen Risk and Cardiovascular
Health Study
The Ludwigshafen Risk and Cardiovascular Health (LURIC) study is an
ongoing prospective cohort study of patients referred for coronary angi-
ography. In total, 3316 subjects were recruited between June 1997 and
May 2001.29 Recruitment was done consecutively on regular working
days and the number of subjects included per day was only limited by
the capacity of the staff involved. There was no deliberate exclusion of
subjects for reasons other than the exclusion criteria specified in the
study protocol. Low-density lipoprotein composition was available in
3266 individuals with coronary angiograms; of these, 1623 with
lipid-lowering drugs were excluded from the analysis. Among the remain-
ing 1643 subjects, 1070 had angiographically proven CAD (≥20% sten-
oses), and 573 had no CAD. Of the 1070 subjects with CAD, 743
presented with stable CAD, while the remaining patients were admitted
with unstable angina pectoris (n ¼ 243), non-ST-elevation myocardial in-
farction (NSTEMI) (TroponinT. 0.1 mg/L,n ¼ 47), orST-elevationmyo-
cardial infarction (STEMI) (TroponinT. 0.1 mg/L, n ¼ 37). During a
median follow-up of 9.9 years, 398 patients died, of these 246 from cardio-
vascular causes according to death certificates obtained from local health
authorities. No patient was lost to follow-up, death certificates were
missing in 13 decedents who were included in the analysis for total mortal-
ity, but excluded from analysis of cardiovascular mortality. The study was
approved by the ethics committee at the ‘A¨rztekammer-Rheinland-Pfalz’.
Informed written consent was obtained from all participants.
Studies of low-density lipoprotein subfractions
To examine the relationship between LDL particle size and the distribu-
tion of LDL subfractions in detail, we studied two groups of patients not
included in the LURIC study: (i) 114 patients with fasting plasma glucose
between 1.1 and 2.0 g/L, established impaired glucose tolerance or type 2
diabetes mellitus not receiving oral antidiabetics, insulin or lipid-lowering
agents (LDL-C . 1.30 g/L, TG. 1.0 g/L);30 (ii) 84 patients with coron-
ary heart disease (CHD) or CHD risk equivalent with LDL-C between
1.0 and 1.6 g/L.31 Of these, 39 had vascular disease (34%) and 76 (90%)
had diabetes mellitus. Low-density lipoprotein subfraction profiles
used for the current evaluation were obtained while all patients were
off lipid-lowering drugs.
Laboratory procedures
Laboratory methods and lipoprotein analysis are described in detail in the
Supplementary material online. In brief, lipoproteins were separated by a
combined ultracentrifugation–precipitation method (n ¼ 1643, LURIC
study) (b-quantification; very-low-density lipoproteins (VLDL), LDL,
HDL)32 or byequilibrium density gradient centrifugation (n ¼ 198, popu-
lation outside the LURIC study) (VLDL, intermediate-density lipopro-
teins (IDL), LDL, six LDL subfractions, HDL).1 The average radius of
LDL was calculated from apoB and major lipids as described.1
Statistical analysis
Participants of the LURIC study were classified into three groups accord-
ing to the calculated mean LDL diameters (Supplementary material
online, Figure S1): large (.16.8 nm), intermediate (16.5–16.8 nm), and
small LDL (,16.5 nm). Clinical and anthropometric characteristics
were compared between these strata by x2-contingency table testing,
ANOVA or logistic regression using covariables as indicated (Table 1).
We used the Cox proportional hazards model to examine the associ-
ation between average LDL size and mortality from all or cardiovascular
causes. As indicated by log-minus-log diagnostic plots, the proportional
hazards assumption was met. Multivariable adjustment was carried out
for age, sex or in addition for CAD status (absence of angiographic
CAD, stable CAD, unstable angina pectoris, NSTEMI, or STEMI), body
mass index, diabetes mellitus, hypertension, smoking, estimated glom-
erular filtration rate, LDL-C, HDL-C, and TG (Figure 1, Table 2).
The assumption that residuals are normally distributed was examined
using plots ofobservedvs. predictedvalues. In noneof the analyses didwe
obtain an indication that this assumption was violated. We are reporting
estimated marginal means of the dependent variables along with their
95% CI. The least significant difference t-test was used for post hoc com-
parisons. The statistical tests were two-sided;P, 0.05 was considered
significant. The SPSS 19.0 statistical package (SPSS Inc.) was used.
Results
Characteristics of study participants
according to mean low-density
lipoprotein diameters
The proportion of men significantly increased in parallel to decreasing
LDL size (Table 1). Patients with small LDL were on average younger
than those with large or intermediate LDL. Current or past smoking,
diabetes mellitus and hypertension were more prevalent among
patients with small LDL. There was no obvious association of LDL
size with angiographic CAD. In parallel to decreasing LDL size, body
mass index, TG, and systolic and diastolic blood pressure increased,
while HDL-C decreased. Low-density lipoprotein cholesterol was
highest among persons with intermediate LDL size, second highest
among those with large LDL, and lowest among those with small LDL.
Low-density lipoprotein size, total
mortality, and mortality from
cardiovascular causes
Mortality from all causes was lowest in patients with intermediate LDL
(16.5–16.8 nm), while it was significantly higher in patients with larger
and smaller LDL.Thisfindingwas robust against adjustment forage and
sex and additional adjustment for other cardiovascular risk factors in-
cluding LDL-C (Figure 1, Table 2, Model 3). The hazard ratios (HRs) of
the fully adjusted model were 1.71 (95% CI: 1.31–2.25) and 1.24 (95%
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CI: 0.95–1.63) for large and small LDL, respectively. Comparable
results were obtained for the association with cardiovascular mortality
(Figure 1, Table 2). Adjustment for apoB instead of LDL-C did not sub-
stantially change the association of LDL size with total and cardiovas-
cular mortality (Supplementary material online, Table S1). There was
no relationship between LDL-C and LDL-apoB with mortality,
neither in theentire study populationnor in anyof theLDLsizegroups.
The association of small LDL with total mortality was stronger in
women than in men (P for interaction ¼ 0.023), while there was no
significant interaction between sex and LDL diameter for the associ-
ation with cardiovascular mortality (P for interaction ¼ 0.759). The
HRs for total and cardiovascular mortality were similar in patients
with and without type 2 diabetes mellitus (P for interaction: 0.182
and 0.745, respectively).
With the b-quantification method, lipoprotein(a) is in the LDL
fraction. Thus, we calculated HRs in a subgroup with lipoprotein(a)
concentrations ,0.30 g/L (n ¼ 1183). The resulting HRs were only
slightly different compared with the entire study population indicat-
ing that lipoprotein(a) did not impact on our findings (Supplementary
material online, Table S2).
The size and composition of LDL are related to the metabolism of
TG-rich lipoproteins.33 However,VLDL-apoBandVLDL-Cwerenot
significantly associated with total or cardiovascular mortality in the
current study (Supplementary material online, Table S3).
Low-density lipoprotein mean particle
diameter and low-density lipoprotein
composition
We investigated the composition of LDL in the strata of LDL size
(Supplementary material online, Table S4). In patients with small
LDL, the concentration of LDL-C was lower compared with those
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Table 1 Clinical characteristics of study participants according to low-density lipoprotein size
LDL size Large Intermediate Small Pa Pb Pc
Particle diameter (nm)d .16.8 16.5–16.8 ,16.5
N 469 470 704
Sex
Men 246 (53%) 289 (62%) 563 (80%) ,0.001e 0.005e ,0.001e
Women 223 (47%) 181 (38%) 168 (20%)
Age (years) 64+11 63+10 61+12 ,0.001f 0.752f 0.001f
Smoking ,0.001g
Never 209 (45%) 210 (45%) 228 (32%)
Previous 161 (34%) 170 (36%) 311 (44%)
Current 99 (21%) 90 (19%) 165 (23%)
Coronary artery disease 0.270g
None 185 (39%) 161 (34%) 227 (32%)
Stable CAD 196 (42%) 210 (45%) 337 (48%)
Unstable (TnT2) 63 (13%) 76 (16%) 104 (15%)
NSTEMI (TnT+) 15 (3%) 15 (3%) 17 (2%)
STEMI (TnT+) 61 (2%) 8 (2%) 19 (3%)
Body mass index (kg/m2) 26.5+4.0 27.3+4.2 28.0+4.2 ,0.001h 0.005h ,0.001h
Diabetes mellitus (%) 124 (26%) 129 (27%) 253 (36%) ,0.001i 0.632i ,0.001i
LDL-C (g/L) 1.24+0.33 1.31+0.32 1.19+30.0 ,0.001h 0.001h 0.001h
HDL-C (g/L) 0.44+0.13 0.42+0.11 0.37+0.09 ,0.001h 0.030h 0.001h
Triglycerides (g/L)j 1.23 (1.18–1.29) 1.31(1.26–1.37) 1.73 (1.67–1.79) ,0.001h 0.042h ,0.001h
Hypertension 325 (69%) 341 (73%) 531 (75%) 0.068i 0.190i 0.016i
Systolic blood pressure (mmHg) 140+23 142+23 144+23 0.001k 0.228k 0.001k
Diastolic blood pressure (mmHg) 81+12 82+11 82+12 0.101k 0.133k 0.608k
aP for trend: large, intermediate, and small LDL.
bPost hoc P (least square difference): large vs. intermediate LDL.
cPost hoc P (least square difference): small vs. intermediate LDL.
dCalculated from apoB and major lipids determined by b-quantification.
eLogistic regression adjusted for age.
fANOVA adjusted for sex.
gx2-test.
hANOVA adjusted for age and sex.
iLogistic regression adjusted for age and sex.
jTriglycerides reported as medians and 25th and 75th percentile; triglycerides were log transformed before being used in ANOVA.
kANOVA adjusted for age, sex, and for use of antihypertensive drugs.
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with intermediate-sized LDL. At the same time, the concentration of
LDL-apoB was not decreased compared with intermediate LDL.
Thus, at a given LDL-C the molar concentration of LDL particles
was higher in individuals with small LDL. Consistently, small LDL con-
tained less lipid molecules per particle than LDL in patients with
intermediate-sized LDL (on average 1503 compared with 1675,
respectively). In patients with large LDL, LDL-C was slightly lower
than in patients with intermediate LDL, but LDL-apoB was much
lower, indicating that these individuals have larger, lipid-rich LDL
(on average 1851 molecules vs. 1675 per particle).
Low-density lipoprotein mean particle
diameter and markers of inflammation
and oxidative stress
Oxidized LDL and Lp-PLA2 were significantly higher in individuals
with small LDL compared with the groups with large and intermedi-
ate LDL. Interestingly, the inflammatory markers C-reactive protein
(CRP) and interleukin (IL)-6 were highest in the group with large LDL
(Table 3). Adjustment for inflammatory markers slightly attenuated
the association of large LDL with mortality, suggesting that inflamma-
tion is involved in the atherogenic effects of these particles (Table 2,
Supplementary material online, Table S5).
Low-density lipoprotein mean particle
diameter and low-density lipoprotein
subfractions
We examined the relationship between the three categories of mean
LDL particle diameters and the distribution of LDL subfractions.
Because LDL subfractions have not been determined by equilibrium
density gradient ultracentrifugation in the LURIC study, we exploited
baseline results obtained in participants of two independent,
previously completed, randomized clinical studies of lipid lowering.
We calculated mean LDL diameters in these patients from the com-
position of the entire LDL fraction (1.0063 kg/L through 1.063 kg/L)
and subsequently stratified the results according to the particle diam-
eter thresholds used LURIC. As LDL contain one molecule apoB per
particle, we considered the apoB contents of LDL subfractions to
reflect the concentrations of particles in each of the density fractions
LDL-1 to LDL-6. Low-density lipoprotein subfraction profiles were
clearly distinct between the groups (Figure 2). In patients with large
LDL, the LDL particle concentrations were almost equal across the
density spectrum with LDL-1 assuming the highest concentration.
In patients with LDL of intermediate mean size, LDL particle concen-
tration reached a peak at LDL-4. Finally, in patients with the smallest
calculated LDL diameters, the concentration of LDL particles was
highest in LDL-6, followed by LDL-5. The compositions of LDL sub-
fractions hardly differed across the strata with different average LDL
sizes, with the exception of an enrichment of TG in the LDL subfrac-
tions in patients with large LDL (Supplementary material online,
Tables S6 and S7). This overall indicates that changes in the calculated
average size of LDL are mainly due to changes in the relative propor-
tions of each of the subfractions rather than to compositional differ-
ences in individual subfractions.
Discussion
This study demonstrates that the mean particle diameter of LDL is
associated with long-term total and cardiovascular mortality in
patients undergoing coronary angiography, essentially independent
of the main acknowledged cardiovascular risk factors. Using the com-
position of LDL inferred from a b-quantification procedure, we
stratified patients into those with large, intermediate, and small
Figure1 Hazard ratios and 95% confidence intervals for total and cardiovascular mortality by low-density lipoprotein size. The study participants
were classified into three groups according to the calculated mean low-density lipoprotein diameters: large (.16.8 nm), intermediate (16.5–
16.8 nm), and small low-density lipoprotein (,16.5 nm). Squares, unadjusted hazard ratios; triangles, adjusted for age and sex; circles, additionally
adjusted for body mass index, diabetes mellitus, hypertension, smoking, clinical status, low-density lipoprotein cholesterol, high-density lipoprotein
cholesterol, triglycerides, and estimated glomerular filtration rate.
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average calculated particle size. Intriguingly, the relationship between
particle size and mortality was U-shaped, placing both patients with
large and small LDL particles at a higher risk of fatal events.
It has been known for long that LDL include a mixture of particles
differing regarding density1– 3 and size.4,6 Experimental studies have
suggested that small dense LDL are particularly atherogenic.7–9,11–13
Epidemiological evidence based on clinical endpoints for a role of
small dense LDL in the development or progression of vascular
disease has, however, been surprisingly sparse. Some studies have
relied on surrogate vascular endpoints only, such as endothelial dys-
function14 or carotid intima media thickness.15,16 In epidemiological
studiesusing nuclearmagnetic resonance spectroscopy todetermine
LDL size, either small LDL26 were predictive for CAD or both small
and large LDL were associated with subclinical atherosclerosis28 or
CAD,27,34 but only in one study the risk estimates were independent
of other lipid parameters.34 Some prospective epidemiological
studies using gradient gel electrophoresis have found small dense
LDL associated with vascular disease after adjusting for either low
HDL or high TG.22,23 The majority of studies, however, did not
show such an independent association.17– 21 This is evidently due
to the fact that high concentrations of small dense LDL are part of
the atherogenic lipid triad (in addition characterized by high TG)
which in turn is a feature of the metabolic syndrome. It is, in this
regard, worth to note that we were able to demonstrate that small
LDL were essentially independently associated with mortality from
all causes and from cardiovascular causes in the current study. Of
interest, we also obtained evidence for adverse effects not only of
predominantly small but also large LDL compared with LDL of inter-
mediate size. This finding is consistent with studies claiming that
buoyant rather than small LDL are associated with atherosclerosis25
and an increased CAD risk.24,35
Tovalidate our approachofusing theaverage calculated diameterof
LDL as a surrogate for the distribution of LDL subfractions, we exam-
ined the relationship between calculated LDL particle diameters and
actual LDL profiles obtained by equilibrium density gradient ultracen-
trifugation. As expected, patients with low-LDL diameters exhibited
distinct preponderance of dense LDL. In patients with LDL of inter-
mediate size, the LDL particle concentration had a peak at LDL-4
(1.037–1.040 kg/L). At the largest average LDL size, the distribution
of LDL particles was almost even, with LDL-1 (1.019–1.031 kg/L)
reaching the highest concentration. The three groups of our mortality
study thus had distinct patterns of LDL subfractions.
Low-density lipoprotein particles can be synthesized via two path-
ways: the lipolysis of TG-rich lipoproteins33 and direct hepatic secre-
tion.36 In our study, the composition of LDL in patients with large,
intermediate, and small LDL differed characteristically. In patients
with large LDL, the LDL-TG concentration and the number of lipid
molecules per particle were highest among the three groups; LDL
were also relatively enriched in TG. It is thus reasonable to assume
that incompletely catabolized remnants of TG-rich lipoproteins
accumulate in these individuals. On the other hand, patients with
smaller LDL had LDL poor in lipids but relatively enriched in choles-
teryl esters. Those small LDL are the product of hydrolysis of
TG-rich precursors by hepatic lipase.33,36 However, some of them
may directly originate from the liver, because there is a substantial
contribution of hepatic synthesis of small LDL to plasma LDL in
hypertriglyceridemia.37
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We sought to evaluate mechanisms underlying the association of
buoyant and dense LDL with adverse vascular outcomes. We there-
fore compared markers of inflammation and oxidative stress
between the strata of different average LDL sizes. We observed ele-
vated concentrations of oxidized LDL in individuals with small LDL
compared with the other groups. Further, Lp-PLA2, which by large
promotes destabilization of atheroslcerotic lesions, was also higher
in this group. It is well conceivable that this finding is attributable to
the preferential association of this enzyme with small LDL.38 Small
dense LDL appear to be cleared from the plasma at a decreased
rate,11 possibly by pathways different from the LDL receptor.39,40
As a consequence of their prolonged time of residence in the circu-
lation and their decreased content of core antioxidants, small dense
LDL are more susceptible to oxidation,41–43 which is in line with the
current findings.
The concentrations of inflammatory markers such as CRP and IL-6
werehighest in patientswith buoyant LDL.The significanceof this un-
expected finding, however, remains elusive at this time. In particular,
it is hard to decide whether systemic inflammation causes the accu-
mulation of buoyant LDL or whether these lipoproteins are them-
selves responsible for the inflammatory reaction. Disorders of LDL
metabolism and low-grade inflammation have so far been conceived
to be atherogenic by completely distinct pathways.44 However, the
TG contents of LDL may be implicated in inflammation and athero-
genesis. In humans, LDL-TG are mainly hydrolyzed by hepatic
lipase, which is subject to modulation by inflammatory cytokines.45,46
Downregulation of lipases is considered to explain, at least in part, the
elevation of TG during the acute phase response.47 Low-grade sys-
temic inflammation could thus be the cause rather than the conse-
quence of the accumulation of buoyant LDL. The observation,
however, that LDL-TG were associated with both CAD and circulat-
ing adhesion molecules independent of CRP is in favorof the idea that
TG-enrichment of LDL might itself be pro-inflammatory.48– 50
Our study has three major limitations. First, it included patients
scheduled for angiography. This hospital-based population may be
not representative of a random population sample. Second, we
excluded subjects receiving lipid-lowering drugs and thus may have
selected individuals with low-LDL-C. Third, estimating the athero-
genicity of LDL with the b-quantification method used here is still
technically demanding and the clinical application of our findings
may therefore not be straightforward. Future investigations will
therefore have to address the question whether other methods to
estimate mean LDL particle size would be equally informative.
In summary, this is the first study to show a significant association
of both, large and small LDL particle size on total and cardio-
vascular mortality. Our results underline the impact of markers of
the LDL metabolism on clinical endpoints beyond elevated LDL-C
concentration.
Supplementary Material
Supplementary material is available at European Heart Journal online.
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Table 3 Estimated marginal means of biological markers according to low-density lipoprotein diametera
LDL size Large (>16.8 nm) Intermediate (16.5–16.8 nm) Small (<16.5 nm) Pb Pc Pd
Oxidized LDL (U/L) 71 (68–73) 75 (72–78) 80 (78–83) ,0.001 0.018 0.004
Lp-PLA2 activity (U/L) 487 (477–498) 492 (482–502) 519 (510–527) 0.009 0.497 ,0.001
C-reactive protein (mg/L) 10.0 (8.7–11.4) 7.8 (6.4–9.11) 6.4 (5.3–7.6) ,0.001 0.020 0.142
IL-6 (ng/L) 5.80 (5.27–6.32) 4.84 (4.33–5.36) 4.59 (4.16–5.02) 0.002 0.011 0.460
aEstimated marginal means and 95%CI obtained in a general linear model (ANOVA)adjusted for age, sex,BMI, diabetes mellitus, hypertension, clinical status atpresentation, estimated
glomerular filtration rate, and use of lipid-lowering drugs.
bOverall P-values.
cPost hoc P (least square difference): large vs. intermediate LDL.
dPost hoc P (least square difference): small vs. intermediate LDL.
Figure 2 Distribution of VLDL, IDL, and low-density lipoprotein
subfractions obtained by equilibrium density gradient ultracentrifu-
gation in 114 patients with fasting glucose between 1.1 and 2.0 g/L,
established impaired glucose tolerance or type 2 diabetes mellitus30
and 84 patients with coronary heart disease or coronary heart
disease risk equivalent with low-density lipoprotein cholesterol
between 1.0 and 1.6 g/L31 stratified according to calculated
average diameters of low-density lipoprotein (1.0063–1.063 kg/L).
Circles, large low-density lipoprotein; triangles, intermediate low-
density lipoprotein; squares, small low-density lipoprotein.
T.B. Grammer et al.36
(Uppsala, Sweden) provided reagents for the determination of oxi-
dized LDL free of charge, but did not assume any other role in this re-
search. We thank the participants of the Ludwigshafen Risk and
Cardiovascular Health Study and the study team either temporarily
or permanently involved in patient recruitment, sample and data
handling, and the laboratory staff at the Ludwigshafen General Hos-
pital and the Universities of Freiburg (Germany), Ulm (Germany),
and Graz (Austria).
Funding
This work was supported by the 6th Framework Program (integrated
project Bloodomics, grant LSHM-CT-2004-503485) and 7th Framework
Program (integrated project AtheroRemo, Grant Agreement number
201668) of the European Union.
Conflict of interest: none declared.
References
1. Baumstark MW, Kreutz W, Berg A, Frey I, Keul J. Structure of human low-density
lipoprotein subfractions, determined by x-ray small-angle scattering. Biochim
Biophys Acta 1990;1037:48–57.
2. Dejager S, Bruckert E, Chapman MJ. Dense low density lipoprotein subspecies with
diminished oxidative resistance predominate in combined hyperlipidemia. J Lipid Res
1993;34:295–308.
3. Griffin BA, Caslake MJ, Yip B, Tait GW, Packard CJ, Shepherd J. Rapid isolation of low
density lipoprotein (LDL) subfractions from plasma by density gradient ultracentri-
fugation. Atherosclerosis 1990;83:59–67.
4. Sata T, Havel RJ, Jones AL. Characterization of subfractions of triglyceride-rich lipo-
proteins separated by gel chromatography from blood plasma of normolipemic and
hyperlipemic humans. J Lipid Res 1972;13:757–768.
5. Otvos JD, Jeyarajah EJ, Bennett DW, Krauss RM. Development of a proton nuclear
magnetic resonance spectroscopic method for determining plasma lipoprotein con-
centrations and subspecies distributions froma single, rapidmeasurement.Clin Chem
1992;38:1632–1638.
6. Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low density
lipoproteins in normal humans. J Lipid Res 1982;23:97–104.
7. Bjornheden T, Babyi A, Bondjers G, Wiklund O. Accumulation of lipoprotein frac-
tions and subfractions in the arterial wall, determined in an in vitro perfusion
system. Atherosclerosis 1996;123:43–56.
8. Campos H, Arnold KS, Balestra ME, Innerarity TL, Krauss RM. Differences in recep-
tor binding of LDL subfractions. Arteriosclerosis Thrombosis Vasc Biol 1996;16:
794–801.
9. Miller BD, Alderman EL, Haskell WL, Fair JM, Krauss RM. Predominance of dense
low-density lipoprotein particles predicts angiographic benefit of therapy in the
Stanford Coronary Risk Intervention Project. Circulation 1996;94:2146–2153.
10. Nigon F, Lesnik P, Rouis M, Chapman MJ. Discrete subspecies of human low density
lipoproteins are heterogeneous in their interaction with the cellular LDL receptor.
J Lipid Res 1991;32:1741–1753.
11. Packard CJ, Demant T, Stewart JP, Bedford D, Caslake MJ, Schwertfeger G,
Bedynek A, Shepherd J, Seidel D. Apolipoprotein B metabolism and the distribution
of VLDL and LDL subfractions. J Lipid Res 2000;41:305–318.
12. Anber V, Griffin BA, McConnell M, Packard CJ, Shepherd J. Influence of plasma lipid
andLDL-subfractionprofile on the interaction between lowdensity lipoproteinwith
human arterial wall proteoglycans. Atherosclerosis 1996;124:261–271.
13. Hurt E, Camejo G. Effect of arterial proteoglycans on the interaction of LDL with
human monocyte-derived macrophages. Atherosclerosis 1987;67:115–126.
14. Vakkilainen J, Makimattila S, Seppala-Lindroos A, Vehkavaara S, Lahdenpera S,
Groop PH, Taskinen MR, Yki-Jarvinen H. Endothelial dysfunction in men with
small LDL particles. Circulation 2000;102:716–721.
15. Liu ML, Ylitalo K, Nuotio I, Salonen R, Salonen JT, Taskinen MR. Association between
carotid intima-media thickness and low-density lipoprotein size and susceptibility of
low-density lipoprotein to oxidation in asymptomatic members of familial combined
hyperlipidemia families. Stroke 2002;33:1255–1260.
16. Skoglund-Andersson C, Tang R, Bond MG, de Faire U, Hamsten A, Karpe F. LDL par-
ticle size distribution is associated with carotid intima-media thickness in healthy
50-year-old men.Arteriosclerosis Thrombosis Vasc Biol 1999;19:2422–2430.
17. Arsenault BJ, Lemieux I, Despres JP, Wareham NJ, Luben R, Kastelein JJ, Khaw KT,
Boekholdt SM. Cholesterol levels in small LDL particles predict the risk of coronary
heart disease in the EPIC-Norfolk ProspectivePopulation Study.EurHeart J2007;28:
2770–2777.
18. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein
particles with the incidence of coronary artery disease in men and women. JAMA
1996;276:875–881.
19. Lamarche B, Tchernof A, Mauriege P, Cantin B, Dagenais GR, Lupien PJ, Despres JP.
Fasting insulin andapolipoproteinB levels and low-density lipoproteinparticle size as
risk factors for ischemic heart disease. JAMA 1998;279:1955–1961.
20. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Despres JP.
Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic
heartdisease inmen. Prospective results fromthe QuebecCardiovascular Study.Cir-
culation 1997;95:69–75.
21. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, Hennekens CH. A pro-
spective study of triglyceride level, low-density lipoprotein particle diameter, and
risk of myocardial infarction. JAMA 1996;276:882–888.
22. Lamarche B, St-PierreAC, Ruel IL, Cantin B, Dagenais GR, Despres JP. A prospective,
population-based study of low density lipoprotein particle size as a risk factor for
ischemic heart disease in men. Can J Cardiol 2001;17:859–865.
23. St-Pierre AC, Ruel IL, Cantin B, Dagenais GR, Bernard PM, Despres JP, Lamarche B.
Comparison of various electrophoretic characteristics of LDL particles and their re-
lationship to the risk of ischemic heart disease. Circulation 2001;104:2295–2299.
24. Campos H, Moye LA, Glasser SP, Stampfer MJ, Sacks FM. Low-density lipoprotein
size, pravastatin treatment, and coronary events. JAMA 2001;286:1468–1474.
25. Hulthe J, Wiklund O, Bondjers G, Wikstrand J. LDL particle size in relation to intima-
media thickness and plaque occurrence in the carotid and femoral arteries inpatients
with hypercholesterolaemia. J Int Med 2000;248:42–52.
26. El Harchaoui K, van der Steeg WA, Stroes ES, Kuivenhoven JA, Otvos JD,
Wareham NJ, Hutten BA, Kastelein JJ, Khaw KT, Boekholdt SM. Value of low-density
lipoprotein particle number and size as predictors of coronary artery disease in ap-
parently healthy men and women: The EPIC-Norfolk ProspectivePopulationStudy. J
Am Coll Cardiol 2007;49:547–553.
27. Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM. Lipoprotein particle
profiles by nuclear magnetic resonance compared with standard lipids and apolipo-
proteins in predicting incident cardiovascular disease in women. Circulation 2009;
119:931–939.
28. Mora S, Szklo M, Otvos JD, Greenland P, Psaty BM, Goff DC Jr, O’Leary DH, Saad MF,
Tsai MY, Sharrett AR. LDL particle subclasses, LDL particle size, and carotid athero-
sclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 2007;
192:211–217.
29. Winkelmann BR, Marz W, Boehm BO, Zotz R, Hager J, Hellstern P, Senges J. Ration-
ale and design of the luric study – a resource for functional genomics, pharmacogen-
omics and long-term prognosis of cardiovascular disease. Pharmacogenomics 2001;2:
S1–73.
30. Scharnagl H, Winkler K, Mantz S, Baumstark MW, Wieland H, Marz W. Inhibition
of HMG-CoA reductase with cerivastatin lowers dense low density lipoproteins
in patients with elevated fasting glucose, impaired glucose tolerance and type 2
diabetes mellitus. Exp Clin Endocrinol Diabetes 2004;112:269–277.
31. Stojakovic T, de Campo A, Scharnagl H, Sourij H, Schmolzer I, Wascher TC,Marz W.
Differential effects of fluvastatin alone or in combination with ezetimibe on lipopro-
tein subfractions in patients at high risk of coronary events. Eur J Clin Invest 2010;40:
187–194.
32. Wanner C, Horl WH, Luley CH, Wieland H. Effects of HMG-CoA reductase inhibi-
tors in hypercholesterolemic patients on hemodialysis.Kidney Int 1991;39:754–760.
33. Packard CJ. Understanding coronary heart disease as a consequence of defective
regulation of apolipoprotein B metabolism. Curr Opin Lipidol 1999;10:237–244.
34. Otvos JD, Collins D, Freedman DS, Shalaurova I, Schaefer EJ, McNamara JR,
Bloomfield HE, Robins SJ. Low-density lipoprotein and high-density lipoprotein par-
ticle subclasses predict coronary events and are favorably changed by gemfibrozil
therapy in the veterans affairs high-density lipoprotein intervention trial. Circulation
2006;113:1556–1563.
35. Campos H,RoedererGO, Lussier-CacanS, Davignon J, KraussRM.Predominanceof
large LDL and reduced HDL2 cholesterol in normolipidemic men with coronary
artery disease. Arteriosclerosis Thrombosis Vasc Biol 1995;15:1043–1048.
36. Ginsberg HN, Le NA, Gibson JC. Regulation of the production and catabolism of
plasma low density lipoproteins in hypertriglyceridemic subjects. J Clin Invest 1985;
75:614–623.
37. Mendivil CO, Zheng C, Furtado J, Lel J, Sacks FM. Metabolism of very-low-density
lipoprotein and low-density lipoprotein containing apolipoprotein C-III and not
other small apolipoproteins. Arteriosclerosis Thrombosis Vasc Biol 2010;30:239–245.
38. Tselepis AD, Dentan C, Karabina SA, Chapman MJ, Ninio E. PAF-degrading acetylhy-
drolase is preferentially associated with dense LDL and VLDL-1 in human plasma.
Catalytic characteristics and relation to the monocyte-derived enzyme. Arterioscler-
osis Thrombosis Vasc Biol 1995;15:1764–1773.
39. Galeano NF, Al-Haideri M, Keyserman F, Rumsey SC, Deckelbaum RJ. Small dense
low density lipoprotein has increased affinity for LDL receptor-independent cell
surface binding sites: a potential mechanism for increased atherogenicity. J Lipid
Res 1998;39:1263–1273.
LDL particle diameter and mortality 37
40. Shepherd J, Caslake MJ, Lorimer AR, Vallance BD, Packard CJ. Fenofibrate reduces
low density lipoprotein catabolism in hypertriglyceridemic subjects. Arteriosclerosis
1985;5:162–168.
41. Chait A, Brazg RL, Tribble DL, Krauss RM. Susceptibility of small, dense, low-density
lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein
phenotype, pattern B. Am J Med 1993;94:350–356.
42. de Graaf J, Hak-Lemmers HL, Hectors MP, Demacker PN, Hendriks JC,
Stalenhoef AF. Enhanced susceptibility to in vitro oxidation of the dense low
density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 1991;11:
298–306.
43. Tribble DL, Rizzo M, Chait A, Lewis DM, Blanche PJ, Krauss RM. Enhanced oxidative
susceptibility and reduced antioxidant content of metabolic precursors of small,
dense low-density lipoproteins. Am J Med 2001;110:103–110.
44. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein
and low-density lipoprotein cholesterol levels in the prediction of first cardiovascu-
lar events. N Engl J Med 2002;347:1557–1565.
45. Feingold KR, Marshall M, Gulli R, Moser AH, Grunfeld C. Effect of endotoxin and
cytokines on lipoprotein lipase activity in mice. Arterioscler Thromb 1994;14:
1866–1872.
46. Goldberg IJ. Lipoprotein lipase and lipolysis: Central roles in lipoprotein metabolism
and atherogenesis. J Lipid Res 1996;37:693–707.
47. Feingold KR, Memon RA, Moser AH, Shigenaga JK, Grunfeld C. Endotoxin and
interleukin-1 decrease hepatic lipase mRNA levels. Atherosclerosis 1999;142:
379–387.
48. Doi H, Kugiyama K, Oka H, Sugiyama S, Ogata N, Koide SI, Nakamura SI, Yasue H.
Remnant lipoproteins induce proatherothrombogenic molecules in endothelial
cells through a redox-sensitive mechanism. Circulation 2000;102:670–676.
49. Huo Y, Ley K. Adhesion molecules and atherogenesis. Acta Physiol Scand 2001;173:
35–43.
50. Marz W, Scharnagl H, Winkler K, Tiran A, Nauck M, Boehm BO, Winkelmann BR.
Low-density lipoprotein triglycerides associated with low-grade systemic inflamma-
tion, adhesion molecules, and angiographic coronary artery disease: the Ludwigs-
hafen Risk and Cardiovascular Health Study. Circulation 2004;110:3068–3074.
T.B. Grammer et al.38
